Online citations, reference lists, and bibliographies.
← Back to Search

Prognostic Factors For Survival After Surgical Palliation Of Malignant Pleural Effusion

J. Pilling, M. Dusmet, G. Ladas, P. Goldstraw
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: To investigate prognostic factors for patient survival after surgical palliation of malignant pleural effusion (MPE). Method: We reviewed 278 consecutive nonoverseas patients (108 men, median age: 60 years [range 26–89]) undergoing 310 surgical procedures for palliation of MPE over a 72-month period. There were 195 thoracoscopic talc pleurodesis, 39 pleuroperitoneal shunts, 38 pleurodesis by an intercostal drain, 29 pleural biopsies alone, and nine long-term drains. Referring physicians provided survival data. The significance of prognostic factors was examined with the log-rank test (Kaplan-Meier), those significant entered a Cox logistic multivariate regression analysis. Results: Follow-up was complete until death (following 264 procedures) and for a median 648 days (range 173–2135) for surviving patients. Overall median postoperative survival was 211 days (95% confidence interval: 169–253). Survival was not significantly different for tumor type or method of palliation. In univarate analysis, preoperative leucocytosis, hypoxemia, raised alanine transaminase, body mass index below 18 and hypoalbuminemia were associated with a significantly reduced postoperative survival. In multivariate analysis, leucocytosis (p < 0.0001), hypoxemia (p = 0.014), and hypoalbuminemia (p < 0.0001) maintained significance. Conclusions: The survival reported demonstrates the necessity of an active approach to palliation of MPE. The identification of prognostic factors will assist the choice of palliative technique. In addition, an appreciation of the influence of selection on survival after surgical palliation of malignant pleural mesothelioma, especially that of unforeseen prognostic factors, is useful when evaluating the results of aggressive treatment such as chemoradiotherapy and radical surgery for these diseases.
This paper references
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/S0003-4975(01)02586-3
Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.
M. Schulze (2001)
Marmon's Principles of Internal Medicine
D C Heimburger (2008)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1097/01.SLA.0000055547.93484.87
Hypoalbuminemia in Acute Illness: Is There a Rationale for Intervention?: A Meta-Analysis of Cohort Studies and Controlled Trials
J. Vincent (2003)
Malnutrition and nutritional assessment
DC Heimburger (2008)
Management of recurrent pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting
M Petrou (1995)
10.1378/CHEST.113.1_SUPPLEMENT.78S
Treating malignant pleural effusions cost consciously.
C. Belani (1998)
10.1378/CHEST.117.1.73
Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.
C. Burrows (2000)
10.1038/sj.bjc.6601242
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer
L. M. Forrest (2003)
10.1016/S0272-5231(05)70082-4
Malignancy metastatic to the pleura.
S. Sahn (1998)
10.1001/ARCHSURG.134.1.36
Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study.
J. Gibbs (1999)
10.1378/CHEST.104.5.1482
Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases.
Á. Sánchez-Armengol (1993)
10.1016/J.ATHORACSUR.2006.05.070
Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma.
J. Pilling (2007)
10.1038/sj.bjc.6601886
The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases
R. Al-Shaiba (2004)
10.1111/j.1440-1843.2005.00763.x
Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series
Y. Aelony (2005)
10.1016/S0003-4975(02)03599-3
Early and late mortality after pleurodesis for malignant pleural effusion.
A. Bernard (2002)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1002/1097-0142(19950201)75:3<801::AID-CNCR2820750309>3.0.CO;2-H
Management of recurrent malignant pleural effusions. The complementary role of talc pleurodesis and pleuroperitoneal shunting
M. Petrou (1995)
10.1016/S1010-7940(01)01130-7
Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.
G. Cardillo (2002)
10.1510/ICVTS.2005.123430
The MARS trial: mesothelioma and radical surgery.
T. Treasure (2006)
10.1016/S1010-7940(00)00422-X
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
O. Genc (2000)



This paper is referenced by
10.1111/j.1440-1843.2011.01986.x
Pleural controversy: Pleurodesis versus indwelling pleural catheters for malignant effusions
P. Maceachern (2011)
10.1159/000342343
The Impact of Tunneled Pleural Catheters on the Quality of Life of Patients with Malignant Pleural Effusions
Natasha F. Sabur (2012)
10.1016/j.jpainsymman.2012.05.002
To drain or not to drain: an evidence-based approach to palliative procedures for the management of malignant pleural effusions.
Annette Beyea (2012)
10.3978/j.issn.2225-319X.2012.10.02
Inflammation in malignant mesothelioma - friend or foe?
Anthony Linton (2012)
10.1093/annonc/mdy275
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D. Planchard (2018)
10.1097/MCP.0000000000000278
Pleural effusions as markers of mortality and disease severity: a state-of-the-art review
Erin M. DeBiasi (2016)
10.1111/1759-7714.12354
Predictors of survival in patients who underwent video‐assisted thoracic surgery talc pleurodesis for malignant pleural effusion
D. W. Yoon (2016)
10.1159/000485934
Procedures Performed during Hospitalizations for Malignant Pleural Effusions: Data from the 2012 National Inpatient Sample
M. Fortin (2018)
10.1111/crj.12292
Prognostic factors affecting survival in non‐small cell lung carcinoma patients with malignant pleural effusions
U. Kasapoğlu (2016)
10.1016/j.arbres.2020.01.004
LENT Score: Predicting the Survival of Malignant Pleural Effusion - A Prospective Study of Three Years.
S. Raimundo (2020)
10.1007/978-3-319-44025-5_8
Thoracic Emergencies: Tracheobronchial, Pulmonary, and Pleural Diseases
L. Erhunmwunsee (2017)
10.1016/j.pneumo.2016.08.001
[Survival of malignant and paramalignant pleural effusions in Ouagadougou].
A. T. Bambara (2016)
10.1002/jso.24168
Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
F. C. Abrão (2016)
10.1055/s-0034-1395796
Medical thoracoscopy.
Joseph H. Skalski (2014)
10.3310/hta24260
Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.
R. Bhatnagar (2020)
10.1016/j.chest.2020.08.2070
Basic and Advanced Pleural Procedures Coding and Professional Fees Update for Pulmonologists.
Neeraj R. Desai (2020)
10.1007/s12199-016-0530-6
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
A. C. Tanrıkulu (2016)
10.1097/CPM.0000000000000084
Surgical Perspectives on Management of Malignant Pleural Effusions
Sudish C. Murthy (2015)
10.1159/000482010
Malignant Pleural Effusions: Mistletoe Spray Instead of Talc Poudrage?
J. Shaw (2017)
10.1016/j.thorsurg.2012.10.001
Surgical management of malignant pleural effusions.
S. Murthy (2013)
10.1093/annonc/mdy474
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D. Planchard (2019)
10.1186/s12935-020-01635-8
A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection
S. Chen (2020)
10.1080/17476348.2018.1398085
Surgical and non-surgical management of malignant pleural effusions
Deirdre B Fitzgerald (2018)
10.1111/1759-7714.13086
Predictors of survival in non‐small cell lung cancer patients with pleural effusion undergoing thoracoscopy
Lixu Xie (2019)
10.3949/ccjm.86a.17095
Managing malignant pleural effusion
A. Wahla (2019)
10.1016/J.PNEUMO.2016.08.001
Survie des pleurésies malignes et paramalignes à Ouagadougou
Augustin Tozoula Bambara (2016)
10.1177/1753466618785098
Contemporary best practice in the management of malignant pleural effusion
C. Koegelenberg (2018)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1177/2373997515600657
Pleural Effusion Size as Prognostic Marker in Patients With Malignant Pleural Effusion: A Retrospective Cohort Study
Felicia Montero-Arias (2015)
10.1097/MD.0000000000003996
Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion
A. Verma (2016)
10.1016/j.clon.2013.08.009
Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival.
S. Murphy (2013)
10.1089/jpm.2013.0617
Quality of life and outcomes after nonintubated versus intubated video-thoracoscopic pleurodesis for malignant pleural effusion: comparison by a case-matched study.
T. Mineo (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar